Skip to NavigationSkip to content

BMS and Array BioPharma partner up to tackle colorectal cancer

Published on 30/05/17 at 12:38pm

Bristol-Myers Squibb and Array BioPharma have announced they are to join forces as part of a new clinical research partnership which aims to combine the latter’s investigational MEK inhibitor binimetinib with the former’s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) regimes to pursue treatment for metastatic colorectal cancer in patients with microsatellite stable tumours.

The partnership will deliver a Phase 1/2 study designed to explore the anti-tumour potential of binimetinib in combination with BMS’ regimens, in addition to its safety, tolerability and efficacy, as well as adequate dosage. The trial is due to begin in the second half of the year.

"Colorectal cancer remains a challenging tumour where immunotherapy benefits have been limited to a subset of patients," explained Fouad Namouni, Senior Vice President, Head of Oncology Development at BMS. "We are committed to investigating a wide range of oncology therapies, and look forward to studying the combination of Array's MEK inhibitor and our immunotherapies with the goal of developing more treatment options for patients."

Array CEO Ron Squarer added: “Array is pleased to announce this new collaboration with Bristol-Myers Squibb. Based on emerging data, we believe that studying combinations of targeted therapies, such as binimetinib, with immuno-oncology agents, such as Opdivo and Yervoy, could provide important scientific advances for patients fighting cancer.”

Colorectal cancer is very prevalent across the world, standing as the third most common cancer type in men and the second in women.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches